Manages hypertension. ANDA 75047, held by Amneal Pharm. Acebutolol Hydrochloride.
As of Nov 16, 2026, ANDA 75047 (Acebutolol Hydrochloride), held by Amneal Pharm, was first approved by FDA on Dec 30, 1999, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Hypertension Acebutolol hydrochloride capsules, USP are indicated for the management of hypertension in adults. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Ventricular Arrhythmias Acebutolol hydrochloride capsules, USP are indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 30, 1999 | Original application | Approved |
| Acebutolol HydrochlorideEQ 200MG BASE · capsule;oral | Acebutolol Hydrochloride | Rx |
| Acebutolol HydrochlorideEQ 400MG BASE · capsule;oral | Acebutolol Hydrochloride | Rx |
| Apr 6, 2015 | Supplement 7Labeling | Approved | None posted |
| Jan 21, 2011 | Supplement 9Manufacturing | Approved | None posted |
| May 22, 2007 | Supplement 3Manufacturing | Approved | None posted |
| May 22, 2007 | Supplement 4Manufacturing | Approved | None posted |
| May 22, 2007 | Supplement 5Manufacturing | Approved | None posted |
| Dec 30, 1999 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters